Company Filing History:
1 out of 832,880 Years Active: 2003
Title: Akio Kakefuda: Innovator in Isoquinoline Derivatives
Introduction
Akio Kakefuda is a notable inventor based in Tsukuba-shi, Ibaraki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on isoquinoline derivatives. His research focuses on developing compounds that can effectively inhibit certain cardiac currents while minimizing side effects.
Latest Patents
Kakefuda holds a patent for isoquinoline derivatives or salts thereof. This compound is particularly relevant as it serves as a drug with an I current inhibitory effect, which is crucial for treating various cardiac conditions. The invention is designed to function as a cardiac rate lowering agent, making it beneficial for preventing ischemic heart diseases such as angina and cardiac infarction, as well as circulatory diseases like congestive cardiac insufficiency and supraventricular arrhythmia. The patent details the synthesis of dialkoxy-1,2,3,4-tetrahydroquinoline-2-carbonylpiperidino-3,4-dialkoxypropaneanilide derivatives, showcasing the innovative nature of his work.
Career Highlights
Throughout his career, Kakefuda has demonstrated a commitment to advancing medical science through his inventions. His focus on isoquinoline derivatives highlights his dedication to developing effective treatments for serious health conditions. His work has the potential to impact the lives of many patients suffering from heart-related ailments.
Collaborations
Kakefuda has collaborated with notable colleagues in his field, including Toshihiro Watanabe and Toshio Okazaki. These partnerships have likely contributed to the depth and breadth of his research, fostering an environment of innovation and discovery.
Conclusion
Akio Kakefuda is a distinguished inventor whose work on isoquinoline derivatives represents a significant advancement in cardiac treatment options. His contributions to the pharmaceutical industry are noteworthy and have the potential to improve patient outcomes in heart disease management.